Roivant Sciences
在场
Roivant Sciences 的所有者是 Sumitomo Chemical.
是其中之一......
Sumitomo Chemical 是一家在股票代码 4005 (JP) 下上市的公司。
Sumitomo Chemical 在 6 个国家有直接业务。Sumitomo Chemical 拥有 28家子公司，其中包括 Asahi Chemical、Ciox Health 和 Covant Therapeutics。
他们在：
高管
查看带有其 299 名主要高管的组织结构图
Roivant Sciences 搜索最多的简介
高管在Roivant Sciences变化
- Mayukh Sukhatme 曾任 Chief Investment Officer and President, 现任 Director, Chief Investment Officer and President (新闻发布的2023十一月10号).
- Hiroshi Nomura, Director, 将于 20238月31 退休 (新闻发布的2023八月7号).
创建提醒
跟踪 Roivant Sciences 的高管变动
生物技术
Sumitomo Chemical 拥有 2,284 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
- WindRose Health Investors has announced the acquisition of SubjectWell (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
Roivant Sciences 的最新新闻稿
- There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It
- JPM Day 3 had a cautiously optimistic outlook
- Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024
- Immunovant stock gains after data for autoimmune therapy
- Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | Roivant Sciences Ltd.
- Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 | Roivant Sciences Ltd.
- Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus | Roivant Sciences Ltd.
- Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update | Roivant Sciences Ltd.
- Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022 | Roivant Sciences Ltd.
- FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years | Roivant Sciences Ltd.
- View more press releases Close
通过电子邮件
